Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC

Lantheus Holdings, Inc. (NASDAQ:LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells.

NM-01 is being investigated in the Phase 2 PELICAN single-arm trial in non-small cell lung cancer (NSCLC) patients.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.